We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 241

Federal Circuit looks for inventive concept in Sequenom patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 10 2014

On November 7, 2014, the Federal Circuit heard oral arguments in Aria Diagnostics, Inc. v. Sequenom, Inc., where Sequenom is appealing the district

District court finds Genetic Technologies patent invalid under 101 on motion to dismiss

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 6 2014

Judge Stark of the U.S. District Court for the District of Delaware granted defendants' motion to dismiss Genetic Technologies, Ltd.'s patent

Federal Circuit judges disagree on use of post filing date evidence of nonobviousness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • October 21 2014

On October 20, 2014, the Federal Circuit issued an order denying the petition for rehearing or rehearing en banc filed in Bristol-Meyers Squibb Co. v

Federal Circuit looks for a different kind of unexpected results in BMS v. Teva

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 2 2014

In Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit affirmed the district court’s finding that BMS’s Baraclude patent

Federal Circuit finds distribution of glucose meters exhausts method patent claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 14 2013

In LifeScan Scotland, Ltd. V. Shasta Technologies, LLC, the Federal Circuit found that LifeScan's distribution of its One-Touch Ultra glucose meters

Patent term adjustment - challenging applicant delays

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 22 2011

Hoffman-La Roche Inc. and Morphosys AG are among the latest patent holders to file a Patent Term Adjustment (PTA) action against the USPTO

USPTO asks for patent subject matter eligibility comments by July 31, 2014

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 30 2014

In a June 30, 2014 Federal Register Notice, the USPTO requested public comments by July 31, 2014 on patent subject matter eligibility under the

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit upholds inequitable conduct defense against Apotex patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 18 2014

In Apotex Inc. v. UCB, Inc., the Federal Circuit upheld the district court's finding that Apotex's patent is unenforceable due to inequitable conduct

Supreme Court oral arguments in ACLU Myriad gene patent case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases-the "ACLUMyriad" gene